<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03249259</url>
  </required_header>
  <id_info>
    <org_study_id>B-1508-312-006</org_study_id>
    <nct_id>NCT03249259</nct_id>
  </id_info>
  <brief_title>The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes</brief_title>
  <official_title>The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators are going to investigate the efficacy of choline alfoscerate
      on improvement of cognitive function assessed by MMSE compared to plaebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will enroll patients with type 2 diabetes whose age is equal to higher than
      60, and randomly assigned study drug or placebo at 1:1 ratio. The treatment duration is 6
      months and extension study will be continued to 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2016</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blind placebo controlled study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>6 months</time_frame>
    <description>Change of MMSE Score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in fasting glucose concentration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of hypoglycemia</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Choline alfoscerate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>choline alfoscerate 400mg (2 caps - 1 cap bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (2 caps - 1 cap bid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Choline alfoscerate</intervention_name>
    <description>Treatment duration is 6 months and can be extended to 12 months with participant's agreement.</description>
    <arm_group_label>Choline alfoscerate</arm_group_label>
    <other_name>Choline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment duration is 6 months and can be extended to 12 months with participant's agreement.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes

          -  baseline MMSE score 25-28

        Exclusion Criteria:

          -  type 1 diabetes

          -  diabetes ketoacidosis or hyperosmolar hyperglycemic crisis

          -  HbA1c over than 9.0%

          -  MMSE less than 25

          -  abnormal TSH levels

          -  vitamin B12 deficiency

          -  severe infection, perioperative state, trauma

          -  hypopituitarism or adrenal insufficiency

          -  any conditions that lead to hospitalization

          -  chronic alcoholics within 1 year

          -  any drugs that can influence to cognitive function within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 9, 2017</study_first_submitted>
  <study_first_submitted_qc>August 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>October 4, 2019</last_update_submitted>
  <last_update_submitted_qc>October 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Soo Lim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

